Voyager Therapeutics. has been granted a patent for compositions and methods involving modulatory polynucleotides. The patent specifically claims an adeno-associated virus (AAV) genome that encodes these polynucleotides, featuring defined flanking and loop regions based on specified nucleotide sequences. GlobalData’s report on Voyager Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Voyager Therapeutics, Adeno-associated virus vectors was a key innovation area identified from patents. Voyager Therapeutics's grant share as of July 2024 was 15%. Grant share is based on the ratio of number of grants to total number of patents.
Modulatory polynucleotides using adeno-associated virus technology
The patent US12071625B2 describes an adeno-associated virus (AAV) viral genome engineered to include a specific nucleotide sequence flanked by inverted terminal repeats (ITRs). This nucleotide sequence encodes a modulatory polynucleotide, which consists of a 5' flanking region, a loop region, and a 3' flanking region, each defined by specific sequences (SEQ ID NOs: 1-14). The claims detail various configurations of these regions, including combinations that may inhibit the expression of the SOD1 gene, which is relevant in certain neurodegenerative diseases. Additionally, the AAV genome may include a passenger strand and a guide strand, with specified complementarity requirements, enhancing its potential for therapeutic applications.
The patent further outlines the composition of recombinant AAV particles that incorporate the described viral genome along with AAV capsid proteins, which may include variants of AAV1, AAV5, or AAV9. It also covers pharmaceutical compositions containing these recombinant particles and methods for treating central nervous system diseases, such as Huntington's disease and Amyotrophic Lateral Sclerosis (ALS). The administration routes for these treatments can vary, including intravenous and intracisternal injections. Overall, the patent presents a framework for utilizing engineered AAVs in gene therapy, particularly targeting neurological conditions.
To know more about GlobalData’s detailed insights on Voyager Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
